Bile Duct Carcinoma malady

Wikipedia: Cholangiocarcinoma is a medical term denoting a form of cancer that is composed of mutated epithelial...⁴⁴ more...

MalaCards: Bile Duct Carcinoma is related to extrahepatic bile duct carcinoma and hepatitis. An important gene associated with Bile Duct Carcinoma is MGAT4A (mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A), and among its related pathways are Renal cell carcinoma and Adhesion. The compounds egcg and h2o2 have been mentioned in the context of this disorder. Affiliated tissues include lymph node, small intestine and liver, and related mouse phenotypes are respiratory system and craniofacial.

Disease Ontology: A carcinoma that starts in the bile duct.⁶

Aliases & Descriptions:

bile duct carcinoma 6 43

Diseases related to bile duct carcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 518)

id	Related Disease	Score	Top Affiliating Genes
1	extrahepatic bile duct carcinoma	36.8	MGAT4A, MGAT4B, FAR2, AKAP3, ST3GAL3
2	hepatitis	30.7	MGAT3, MGAT5, FASLG, FAS, KRT8, TGFB1
3	bile duct cancer	29.8	BCL2, FSCN1, CDKN2A, ERBB2
4	cholangitis	29.4	MUC2, CDKN2A, CDX2, TP53, PPARG, SLPI
5	intrahepatic cholangiocarcinoma	25.6	VEGFC, BCL2, MUC1, MUC2, MUC4, MUC6
6	carcinoma	22.9	PIK3CG, KIT, GCNT2, VEGFC, MYC, BCL2
7	hepatitis b	21.7	PIK3CG, VEGFC, MYC, BCL2, MUC1, CEBPB
8	retinoblastoma	21.0	PIK3CG, KIT, VEGFC, MYC, BCL2, MUC1
9	adenocarcinoma	17.0	PIK3CG, KIT, GCNT2, VEGFC, MYC, BCL2
10	biliary papillomatosis	13.7	MUC1, MUC2, MUC6
11	ampulla of vater adenocarcinoma	13.7	MUC1, MUC2, CDX2
12	pancreatic ductal carcinoma	13.6	MUC2, MUC6, FASLG, KRT8
13	small intestine adenocarcinoma	13.6	MUC1, MUC2, CDX2
14	pseudomyxoma peritonei	13.6	MUC2, MUC6, CDX2, CDH1
15	lynch syndrome	13.6	MUC2, MUC6, CD44
16	bronchiolo-alveolar adenocarcinoma	13.5	MUC2, MUC4, MUC6, CDX2, CDH1
17	neuroendocrine tumor	13.4	CDX2, KRT8, GFRA1, SYP, GDNF
18	mesenchymal cell neoplasm	13.4	CD44, CCND1, SYP
19	dry eye syndrome	13.4	MUC1, MUC4, CD44, GDNF
20	microinvasive gastric cancer	13.4	VEGFC, MUC2, CDX2, CDH1, CTNNA1
21	ameloblastic carcinoma	13.4	SDC1, MUC1, TP63
22	merkel cell carcinoma	13.4	KIT, MUC1, KRT8, SYP
23	carcinoid syndrome	13.4	MUC1, FSCN1, CDX2, KRT8, SYP
24	multiple endocrine neoplasia type 2a	13.4	MAPK8, GFRA1, GDNF
25	superficial spreading melanoma	13.4	MYC, CDKN2A, CCND1
26	bowenoid papulosis	13.4	CDKN2A, TERT, PPARG
27	pulmonary large cell neuroendocrine carcinoma	13.3	CDKN2A, TP63, KRT8
28	ovarian mucinous adenocarcinoma	13.3	MUC2, CDX2, TP53
29	perivascular epithelioid cell tumor	13.3	KIT, MUC1, CDKN2A, SYP
30	pulmonary sclerosing hemangioma	13.3	MYC, MUC1, CDH1, SYP
31	desmoid tumor	13.3	KIT, CDKN2A, CCND1, CTNNA1
32	malignant peripheral nerve sheath tumor	13.3	KIT, MUC1, CDKN2A, TERT
33	lymphoma, small cleaved-cell, diffuse	13.2	BCL2, CCND1
34	acth-secreting pituitary adenoma	13.2	CDKN2A, CCND1, PPARG
35	sarcomatoid renal cell carcinoma	13.2	KIT, MUC1, CDH1, FAS
36	adenosquamous carcinoma	13.2	MUC1, MUC2, MUC4, TP63, KRT8
37	chromophobe renal cell carcinoma	13.2	KIT, MUC1, CCND1, CAV1, KRT8
38	mucoepidermoid carcinoma	13.2	MUC1, MUC2, MUC4, TP63, CTNNA1
39	biphasic synovial sarcoma	13.2	BCL2, MUC1, CDH1
40	anaplastic carcinoma	13.2	MUC1, CDH1, TP63, KRT8
41	carney complex	13.2	KIT, CCND1, SYP
42	neuroendocrine carcinoma of the cervix	13.2	TP53, SYP
43	angiofibroma	13.1	KIT, MYC, CDH1, CTNNA1
44	intraocular melanoma	13.1	VEGFC, CDKN2A, PTK2, KRT8
45	microglandular adenosis	13.1	KIT, MUC1, ERBB2
46	intestine carcinoma in situ	13.1	FASLG, FAS, ERBB2
47	male breast cancer	13.1	MYC, ERBB2, SYP
48	polymorphous low-grade adenocarcinoma	13.1	KIT, MUC1, TP63
49	superficial urinary bladder cancer	13.1	CCND1, TP53
50	htlv-1 associated myelopathy	13.1	MYC, FASLG, FAS

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to bile duct carcinoma:

²²

MGI Mouse Phenotypes related to bile duct carcinoma:

²⁵ (show all 27)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.5	TP63
2	craniofacial phenotype	MP:0005382	9.8	POSTN, RPSA, TP73, MAPK8, CDKN1C, KIT
3	liver/biliary system phenotype	MP:0005370	9.7	KIT, TP53
4	endocrine/exocrine gland phenotype	MP:0005379	9.6	CDX2, CDKN1C, GALNT3, POSTN, TAS1R1, RPSA
5	taste/olfaction phenotype	MP:0005394	9.2	TAS1R2, TAS1R1, TAS1R3, TERT, TP63, MAPK1
6	renal/urinary system phenotype	MP:0005367	8.5	GFRA1, TP63, CAV1, MGAT5, CDKN1C, CEBPB
7	limbs/digits/tail phenotype	MP:0005371	8.4	PTK2, CTNNA1, POSTN, GALNT3, TP63, ERBB2
8	embryogenesis phenotype	MP:0005380	8.3	GFRA1, KRT8, CTNNA1, PTK2, TP73, TP63
9	no phenotypic analysis	MP:0003012	7.6	PPARG, PTK2, TP53, MGAT4A, CDH1, CD44
10	behavior/neurological phenotype	MP:0005386	7.4	CAV1, TP73, PPARG, GFRA1, GDNF, MAPK1
11	immune system phenotype	MP:0005387	7.2	TERT, TP63, TP53, CCND1, MGAT5, CDKN1C
12	adipose tissue phenotype	MP:0005375	6.8	TGFB1, PLAU, PPARG, TP53, CAV1, MAPK8
13	reproductive system phenotype	MP:0005389	6.5	GDNF, GALNT3, POSTN, CD44, CDKN1C, CDX2
14	mortality/aging	MP:0010768	6.2	TP53, TP73, PTK2, CTNNA1, PPARG, PLAU
15	skeleton phenotype	MP:0005390	5.9	TP53, TP63, TP73, TERT, CTNNA1, PPARG
16	vision/eye phenotype	MP:0005391	5.7	CCND1, TP53, TP63, TP73, PPARG, PLAU
17	muscle phenotype	MP:0005369	4.4	TP53, TP63, PTK2, PPARG, PLAU, GFRA1
18	digestive/alimentary phenotype	MP:0005381	4.0	GDNF, FAS, FASLG, CDH1, CD44, CDKN1C
19	integument phenotype	MP:0010771	3.8	MAPK8, CCND1, CAV1, ERBB2, TP53, TP63
20	nervous system phenotype	MP:0003631	3.7	PLAU, PPARG, CTNNA1, PTK2, TERT, GFRA1
21	tumorigenesis	MP:0002006	3.7	MYC, KIT, POSTN, FASLG, MGAT5, MGAT3
22	cardiovascular system phenotype	MP:0005385	3.2	CAV1, CCND1, MAPK1, MAPK8, FAS, FASLG
23	growth/size phenotype	MP:0005378	2.8	PTK2, TERT, TP73, TP63, TP53, ERBB2
24	cellular phenotype	MP:0005384	2.3	POSTN, CAV1, CCND1, MAPK1, MAPK8, FAS
25	homeostasis/metabolism phenotype	MP:0005376	2.0	GALNT3, SLPI, POSTN, TGFB1, PLAU, PPARG
26	hematopoietic system phenotype	MP:0005397	INF	EBAG9, , ST6GAL1, KRT8, RPSA, TP73
27	normal phenotype	MP:0002873	INF	TP63, TERT, GFRA1, SYP, ST6GAL1, FASLG

Articles related to bile duct carcinoma:

(show all 44)

id	Title	Authors	Year	Affiliating Genes
1	Down-regulation of c-Myc expression inhibits the inva sion of bile duct carcinoma cells. (21557726)	Li Z.R.... Shi Y.Z.	2011	MYC
2	Expression of the extracellular matrix protein perios tin in liver tumours and bile duct carcinomas. (20459570)	Riener M.O.... Kristiansen G.	2010	POSTN
3	Decreased expression of focal adhesion kinase is asso ciated with a poor prognosis in extrahepatic bile duct carcinoma. (20185162)	Hayashi A.... Tsuneyoshi M.	2010	PTK2
4	67-kDa laminin receptor in human bile duct carcinoma. (19182490)	Li D.... Wang S.	2009	RPSA
5	Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. (19460356)	Han P.... Chen Q.X.	2009	TP53
6	Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma. (19420730)	Ohashi M.... Kijima H.	2009	CDH1, SDC1
7	Prognostic significance of fascin expression in extra hepatic bile duct carcinomas. (19556073)	Won K.Y.... Kim Y.W.	2009	FSCN1
8	IMP3 expression in lesions of the biliary tract: a ma rker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. (19467694)	Riener M.O.... Kristiansen G.	2009	IGF2BP3, IMP3
9	Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-. (17361208)	Inoue T.... Tsuneyoshi M.	2007	GALNT3
10	Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas. (17396144)	Hong S.M.... Yu E.	2007	KIT
11	Mucin-producing bile duct carcinoma arising from primary sclerosing cholangitis: a case report. (17384480)	Yokomuro S.... Tajiri T.	2007	SLPI
12	CCAAT/Enhancer-binding protein beta regulates expression of human T1R3 taste receptor gene in the bile duct carcinoma cell line, HuCCT1. (17928076)	Toyono T.... Toyoshima K.	2007	CEBPB, TAS1R1, TAS1R2
13	p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance. (17385050)	Hong S.M.... Zaika A.I.	2007	TP63, TP73
14	Impact of lymph node micrometastasis in hilar bile duct carcinoma patients. (16688800)	Taniguchi K.... Uemoto S.	2006	VEGFC, KRT8
15	Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas. (16390235)	Hong S.M.... Yu E.	2006	CDKN2A
16	Expression of PPAR-gamma in human hilar bile duct carcinoma cell line QBC939 and the effects of PPAR-Y activated by its ligand on the growth of QBC939 (17037742)	Cheng W.... Jing J.	2006	PPARG
17	Combined total hepatectomy, orthotopic liver transplantation and pancreatoduodenectomy for unresectable hilar bile duct carcinoma (16635386)	He X.S.... Huang J.F.	2006	KRT9
18	The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines. (16525641)	Miyata H.... Chayama K.	2006	MAPK1, MAPK8, PIK3CG
19	MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. (16857800)	Tamada S.... Yonezawa S.	2006	MUC1, MUC4
20	Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance. (16084941)	Hong S.M.... Ro J.Y.	2005	SYP
21	CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. (16191504)	Hong S.M.... Ro J.Y.	2005	MUC2, CDX2
22	Aberrant expression of pyloric gland-type mucin in mucin-producing bile duct carcinomas: a clear difference between the core peptide and the carbohydrate moiety. (15998373)	Goto M.... Yonezawa S.	2005	MUC6
23	The effect of hepatitis B virus X gene transfection on expression of human telomerase reverse transcriptase mRNA in human bile duct carcinoma cell lines (15598376)	Qu Z.L.... Wang X.	2004	TERT
24	Correlation of glycosyltransferases mRNA expression in extrahepatic bile duct carcinoma with clinical pathological characteristics. (15138129)	Jin X.L.... Chen H.L.	2004	ST6GAL1, MGAT5
25	Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma. (15138553)	Murakami M.... Chayama K.	2004	FAS, FASLG
26	Alteration in N -acetylglucosaminyltransferase activities and glycan structure in tissue and bile glycoproteins from extrahepatic bile duct carcinoma. (15238704)	Jin X.L.... Chen H.L.	2004	GCNT2, MGAT5, MGAT3
27	The expression and significance of human telomerase reverse transcriptase protein and gene in bile duct carcinomas and their adjacent tissues (15059327)	Qu Z.L.... Zhen S.L.	2004	TERT
28	Caveolin-I overexpression is a favourable prognostic factor for patients with extrahepatic bile duct carcinoma. (12737162)	Murakami S.... Katoh H.	2003	CAV1
29	Expression of glial cell line-derived neurotrophic factor correlates with perineural invasion of bile duct carcinoma. (11815973)	Iwahashi N.... Takahashi M.	2002	GDNF, GFRA1
30	Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. (12685548)	Tamada S.... Yonezawa S.	2002	MUC1, MUC2
31	RCAS1 expression as a prognostic factor after curative surgery for extrahepatic bile duct carcinoma. (11986191)	Suzuoki M.... Katoh H.	2002	EBAG9
32	Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. (12028409)	Ito Y.... Matsuura N.	2002	CCND1, CDKN1C
33	Significant correlations of E-cadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas. (11554165)	Mikami T.... Okayasu I.	2001	CDH1, CD44, CTNNA1
34	Fas-Fas ligand pathway does not actively work in extrahepatic bile duct carcinoma. (10928141)	Ito Y.... Matsuura N.	2000	FAS
35	ets-1 expression in extrahepatic bile duct carcinoma and cholangiocellular carcinoma. (10765128)	Ito Y.... Matsuura N.	2000	ETS1
36	Abnormal distribution of collagen type IV in extrahepatic bile duct carcinoma. (11107064)	Chen Y.... Tokunaga O.	2000	TGFB1
37	Expression and clinical implications of bcl-2 in extrahepatic bile duct carcinoma: its relationship with biological features. (11268472)	Ito Y.... Matsuura N.	2000	BCL2
38	Alterations of retinoblastoma protein and p16INK4 protein expression in extrahepatic bile duct carcinomas. (11100316)	Cui X.... Makuuchi M.	2000	CDKN2A
39	Well-differentiated adenocarcinoma, gastric foveolar type, of the extrahepatic bile ducts: A previously unrecognized and distinctive morphologic variant of bile duct carcinoma. (10196386)	Albores-Saavedra J.... Henson D.E.	1999	KRT8
40	Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis. (10570420)	Takao S.... Aikou T.	1999	MUC1
41	Decreased p27(Kip1) expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. (10534337)	Hui A.M.... Takayama T.	1999	CCND1
42	Transcriptional regulation of the N-acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC-T1) is mediated by Ets-1. (8900148)	Kang R.... Taniguchi N.	1996	MGAT5
43	The role of urokinase type plasminogen activator in invasion of bile duct carcinoma (9275473)	Wang S.... Duan H.	1996	PLAU
44	Evaluation of immunoreactivity to erbB-2 protein as a marker of prognosis in bile duct carcinoma (1361658)	Motojima K.... Kanematsu T.	1992	ERBB2

Genes related to bile duct carcinoma according to GeneCards:

(show top 50)    (show all 54)

id	Symbol	Description	Score	GeneCards Section Context
1	MGAT4A	mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A	11.0	Publications
2	IMP3	IMP3, U3 small nucleolar ribonucleoprotein, homolog (yeast)	11.0	Publications
3	TAS1R3	taste receptor, type 1, member 3	11.0	Publications
4	KRT9	keratin 9	11.0	Publications
5	TAS1R2	taste receptor, type 1, member 2	11.0	Publications
6	EBAG9	estrogen receptor binding site associated, antigen, 9	11.0	Publications
7	MGAT3	mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase	11.0	Publications
8	TAS1R1	taste receptor, type 1, member 1	11.0	Publications
9	GALNT3	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3)	11.0	Publications
10	FSCN1	fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)	11.0	Publications
11	SDC1	syndecan 1	11.0	Publications
12	MUC6	mucin 6, oligomeric mucus/gel-forming	11.0	Publications
13	MUC2	mucin 2, oligomeric mucus/gel-forming	11.0	Publications
14	POSTN	periostin, osteoblast specific factor	11.0	Publications
15	RPSA	ribosomal protein SA	11.0	Publications
16	CDKN1C	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	11.0	Publications
17	KRT8	keratin 8	11.0	Publications
18	CEBPB	CCAAT/enhancer binding protein (C/EBP), beta	11.0	Publications
19	CDX2	caudal type homeobox 2	11.0	Publications
20	MGAT5	mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase	11.0	Publications
21	IGF2BP3	insulin-like growth factor 2 mRNA binding protein 3	11.0	Publications
22	MUC4	mucin 4, cell surface associated	11.0	Publications
23	SLPI	secretory leukocyte peptidase inhibitor	11.0	Publications
24	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	11.0	Publications
25	CTNNA1	catenin (cadherin-associated protein), alpha 1, 102kDa	11.0	Publications
26	SYP	synaptophysin	11.0	Publications
27	ETS1	v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)	11.0	Publications
28	GDNF	glial cell derived neurotrophic factor	11.0	Publications
29	GFRA1	GDNF family receptor alpha 1	11.0	Publications
30	CAV1	caveolin 1, caveolae protein, 22kDa	11.0	Publications
31	TERT	telomerase reverse transcriptase	11.0	Publications
32	TP73	tumor protein p73	11.0	Publications
33	VEGFC	vascular endothelial growth factor C	11.0	Publications
34	FASLG	Fas ligand (TNF superfamily, member 6)	11.0	Publications
35	MUC1	mucin 1, cell surface associated	11.0	Publications
36	FAS	Fas (TNF receptor superfamily, member 6)	11.0	Publications
37	CCND1	cyclin D1	11.0	Publications
38	MAPK8	mitogen-activated protein kinase 8	11.0	Publications
39	CD44	CD44 molecule (Indian blood group)	11.0	Publications
40	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	11.0	Publications
41	TP63	tumor protein p63	11.0	Publications
42	MYC	v-myc myelocytomatosis viral oncogene homolog (avian)	11.0	Publications
43	CDKN2A	cyclin-dependent kinase inhibitor 2A	11.0	Publications
44	PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	11.0	Publications
45	PLAU	plasminogen activator, urokinase	11.0	Publications
46	CDH1	cadherin 1, type 1, E-cadherin (epithelial)	11.0	Publications
47	PTK2	PTK2 protein tyrosine kinase 2	11.0	Publications
48	PPARG	peroxisome proliferator-activated receptor gamma	11.0	Publications
49	ERBB2	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)	11.0	Publications
50	GCNT2	glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)	11.0	Publications

Pathways related to bile duct carcinoma according to GeneDecks:

(show top 50)    (show all 95)

id	Pathway	Score	Top Affiliating Genes
1	Renal cell carcinoma20	10.6	ETS1
2	Adhesion3	10.5	CTNNA1, CD44
3	Termination of O-glycan biosynthesis38	10.3	MUC4, MUC2, MUC1, MUC6
4	ErbB2-ErbB3 Heterodimers36	10.3	ERBB2
5	Germ Cell-Sertoli Cell Junction Dynamics36	10.0	TGFB1, CTNNA1, MAPK8
6	Colorectal cancer20	9.9	PIK3CG, MAPK8, TGFB1
7	Acute myeloid leukemia20	9.9	PIK3CG, CCND1, MYC, KIT
8	Glioma Invasiveness36	9.8	PLAU, VEGFC, CD44, PTK2
9	Development HGF signaling pathway10	9.6	SDC1, MAPK1, PLAU, FAS, MAPK8
10	Neurotrophin signaling pathway20	9.5	PIK3CG, FASLG, MAPK8, MAPK1, TP73
11	Non-small cell lung cancer20	9.4	PIK3CG, CDKN2A, MAPK1, ERBB2
12	Akt Signaling36	9.4	PIK3CG, CCND1, KIT, VEGFC, PTK2
13	Development_HGF signaling pathway41	9.3	MAPK1, SDC1, CDH1, FAS, MAPK8, PLAU
14	Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR210	9.2	MAPK1, MYC, MAPK8, BCL2
15	Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR241	9.2	MYC, BCL2, MAPK8, MAPK1
16	p53 signaling pathway20	9.1	CCND1, TP73, FAS, CDKN2A, TP53
17	Development Prolactin receptor signaling10	9.1	BCL2, CEBPB, MYC, MAPK1, CCND1
18	Development_Prolactin receptor signaling41	9.1	BCL2, CEBPB, MYC, MAPK1, CCND1
19	Rac1 Pathway36	9.1	MAPK1, MAPK8, PTK2, TGFB1
20	Development_EGFR signaling pathway41	9.0	MAPK1, MYC, MAPK8, ERBB2, PTK2
21	Chagas disease (American trypanosomiasis)20	8.9	PIK3CG, FAS, MAPK1, MAPK8, TGFB1, FASLG
22	Measles20	8.9	FASLG, PIK3CG, CCND1, TP53, TP73, FAS
23	ErbB signaling pathway20	8.8	MYC, PIK3CG, MAPK1, ERBB2, PTK2, MAPK8
24	Glioma20	8.7	CCND1, PIK3CG, CDKN2A, MAPK1, TP53
25	TGF-beta Signaling Pathways37	8.7	MAPK1, PPARG, PIK3CG, MAPK8, MYC, TGFB1
26	Cell cycle20	8.6	CDKN2A, MYC, TGFB1, TP53, CDKN1C, CCND1
27	ILK Signaling36	8.6	VEGFC, CEBPB, CDH1, KIT, MAPK8, MAPK1
28	WNT Signaling36	8.6	TP53, CTNNA1, MAPK8, CDH1, CEBPB, MYC
29	EGF Pathway36	8.5	MAPK1, ERBB2, CAV1, MAPK8, CDH1, MUC1
30	Melanoma20	8.5	TP53, CDH1, CDKN2A, CCND1, MAPK1, PIK3CG
31	Thyroid cancer20	8.4	MAPK1, MYC, CDH1, CCND1, TP53, PPARG
32	Apoptosis20	8.4	FASLG, PIK3CG, BCL2, FAS, TP53
33	14-3-3 Induced Intracellular Signaling36	8.4	TP73, ERBB2, MAPK1, TGFB1, VEGFC, MAPK8
34	Small cell lung cancer20	8.3	CCND1, PIK3CG, MYC, BCL2, TP53, PTK2
35	ERK Signaling36	8.2	ERBB2, PTK2, TGFB1, MAPK1, MYC, VEGFC
36	JNK Pathway36	8.1	KIT, BCL2, CEBPB, MAPK8, TP53, TGFB1
37	Apoptosis and survival_Role of CDK5 in neuronal death and survival41	8.1	MAPK1, ERBB2, BCL2, TP53
38	Chronic myeloid leukemia20	8.0	PIK3CG, TGFB1, MYC, CDKN2A, MAPK1, CCND1
39	Prostate cancer20	8.0	CCND1, MAPK1, ERBB2, BCL2, PIK3CG, TP53
40	Focal adhesion20	8.0	PTK2, ERBB2, CAV1, CCND1, MAPK1, MAPK8
41	Endometrial cancer20	8.0	ERBB2, CDH1, TP53, CTNNA1, PIK3CG, MYC
42	Bladder cancer20	8.0	VEGFC, MYC, CCND1, TP53, ERBB2, MAPK1
43	Estrogen Pathway36	7.9	TGFB1, KIT, VEGFC, BCL2, MAPK8, CCND1
44	Colorectal Cancer Metastasis36	7.9	CDH1, MAPK1, CCND1, TP53, TGFB1, MYC
45	Pancreatic Adenocarcinoma36	7.1	TGFB1, BCL2, CDKN2A, MAPK1, CCND1, TP53
46	Rho Family GTPases36	6.8	CDH1, BCL2, MAPK1, KIT, TGFB1, PTK2
47	MAPK Signaling36	6.7	KIT, TGFB1, PTK2, TP53, ERBB2, MAPK1
48	Molecular Mechanisms of Cancer36	6.2	CDKN2A, CDH1, MAPK8, MAPK1, CCND1, TP53
49	Pathways in cancer20	5.8	MAPK1, PIK3CG, VEGFC, MYC, BCL2, CCND1
50	N-Glycan biosynthesis20	INF	, MGAT3, MGAT4A, MGAT5, ST6GAL1

Compounds related to bile duct carcinoma according to GeneDecks:

(show top 50)    (show all 209)

id	Compound	Score	Top Affiliating Genes
1	egcg32	10.3	PIK3CG, MAPK8, RPSA
2	h2o232	9.9	GDNF, PIK3CG, MAPK8, SYP
3	threonine32	9.8	MUC2, KRT8, CAV1
4	rapamycin32 42	10.5	KIT, PIK3CG, PTK2, TERT, MAPK8
5	sp 60012532 42	10.4	TP53, PIK3CG
6	hematoxylin32	8.8	MUC1, KIT, CDKN2A, SLPI, TP63, KRT8
7	sb 20358032 42	9.6	CCND1, ETS1, PTK2, PPARG, PLAU, CDH1
8	12-o-tetradecanoylphorbol 13-acetate32	8.3	MYC, FSCN1, MUC2, MAPK8, PLAU, CEBPB
9	mg 13232 42	9.2	FAS, CCND1, MAPK1, FASLG, CDH1, CDKN2A
10	trastuzumab32 34 9 9	11.2	MUC1, VEGFC, PLAU, ERBB2, CCND1, MAPK1
11	estrogen32	8.0	PPARG, RPSA, KRT8, SYP, POSTN, SLPI
12	n acetylcysteine32	8.0	CEBPB, CDKN2A, CDH1, CCND1, ERBB2, TP53
13	5-aza-2deoxycytidine32	7.9	TERT, MYC, CDKN2A, CDX2, CDKN1C, CTNNA1
14	ag 147832	7.8	FASLG, MAPK8, MAPK1, CCND1, PTK2, PLAU
15	depsipeptide32	7.7	MYC, TP53, BCL2, CDKN2A, CDH1, FASLG
16	agarose32	7.7	MUC2, SLPI, TGFB1, FAS, CD44, CDKN2A
17	cysteine32	7.6	GDNF, MUC2, CDKN2A, MUC1, CDX2, CD44
18	ly29400232	7.2	MUC2, PIK3CG, CD44, GDNF, FASLG, MAPK8
19	progesterone32 42 9 18 9	11.1	KIT, VEGFC, BCL2, MUC4, MUC6, CEBPB
20	imatinib32 34 9 9	10.0	MYC, KIT, PIK3CG, BCL2, FASLG, MAPK8
21	suberoylanilide hydroxamic acid32	6.8	MYC, BCL2, CDH1, FASLG, FAS, MAPK8
22	matrigel32	6.8	TP63, PTK2, PLAU, RPSA, KRT8, TGFB1
23	doxorubicin32 34 9 9	9.7	PIK3CG, KIT, CD44, CDH1, FASLG, FAS
24	testosterone32 9 18 9	9.7	FAS, CAV1, FASLG, KIT, VEGFC, MUC1
25	wortmannin32 42	7.6	TERT, PIK3CG, BCL2, CDH1, FASLG, FAS
26	docetaxel32 34 9 9	9.6	ERBB2, CDH1, CDKN2A, BCL2, KIT, MYC
27	resveratrol32 9 18 9	9.6	BCL2, TP53, PTK2, PPARG, MAPK8, FAS
28	5fluorouracil32	6.6	TP53, TP73, TERT, PTK2, ERBB2, FAS
29	arsenite32 18	7.5	TGFB1, TP53, TERT, BCL2, PIK3CG, MYC
30	adriamycin32	6.5	CCND1, ERBB2, TP53, TP73, TERT, PLAU
31	thymidine32 18	7.2	CDX2, FASLG, FAS, CD44, MAPK1, KIT
32	phosphatidylinositol32	6.1	PIK3CG, KIT, VEGFC, MYC, BCL2, MUC4
33	etoposide32 42 9 9	9.0	PTK2, RPSA, KRT8, TGFB1, TERT, TP53
34	tamoxifen32 34 9 9	8.9	SLPI, TGFB1, MYC, BCL2, MUC1, CD44
35	pd 98,05932	5.9	PIK3CG, KIT, VEGFC, MYC, BCL2, MUC2
36	retinoic acid32 42 18	7.8	FAS, MAPK8, CCND1, ETS1, TP73, TERT
37	curcumin32	5.6	PIK3CG, MYC, BCL2, CDH1, MAPK8, MAPK1
38	genistein32 9 18 9	8.4	FAS, FASLG, CDH1, CDKN2A, BCL2, MYC
39	dexamethasone32 42 34 9 9	9.2	FASLG, FAS, MAPK8, MAPK1, CAV1, ERBB2
40	actinomycin d32	5.2	KRT8, TGFB1, SLPI, GDNF, PLAU, TP73
41	oligonucleotide32	5.2	KIT, VEGFC, MYC, BCL2, MUC2, MUC4
42	butyrate32	5.1	MAPK1, TERT, CCND1, TP53, PTK2, PLAU
43	paclitaxel32 34 9 9	7.7	CDH1, FASLG, FAS, MAPK8, MAPK1, CCND1
44	paraffin32	4.6	TP63, TP73, TERT, CTNNA1, PLAU, KRT8
45	tyrosine32	4.4	MUC1, MUC4, CEBPB, FSCN1, CDX2, CD44
46	cycloheximide32	4.3	PIK3CG, TGFB1, SLPI, KRT8, PLAU, PPARG
47	cisplatin32 34 9 9	7.2	MYC, BCL2, MUC1, CDKN2A, CD44, CDH1
48	vegf32	4.1	PLAU, KRT8, TGFB1, SYP, POSTN, SLPI
49	serine32	3.5	GDNF, SLPI, SYP, TGFB1, KRT8, PLAU
50	polysaccharide32	INF	MGAT4A, TGFB1, MGAT3, PLAU, GCNT2,

Cellular components related to bile duct carcinoma according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	Golgi membrane	GO:000139	INF	GALNT3, EBAG9, , ST6GAL1, CAV1, MGAT5
2	Golgi lumen	GO:005796	9.3	SDC1, TGFB1, MUC6, MUC4, MUC2, MUC1
3	focal adhesion	GO:005925	9.0	PTK2, CAV1, MAPK1, CDH1, SDC1, EBAG9

Biological processes related to bile duct carcinoma according to GeneDecks:

(show all 40)

id	Name	GO ID	Score	Top Affiliating Genes
1	post-translational protein modification	GO:043687	INF	MUC1, GALNT3, , ST6GAL1, MGAT5,
2	cellular protein metabolic process	GO:044267	INF	GALNT3, , ST6GAL1, RPSA, MGAT5,
3	detection of chemical stimulus involved in sensory perception of sweet taste	GO:001582	10.3	TAS1R2, TAS1R3
4	cellular response to hyperoxia	GO:071455	10.2	CAV1, FAS
5	cell motility	GO:048870	10.2	PTK2, ETS1, FSCN1
6	inflammatory cell apoptotic process	GO:006925	10.2	FAS, FASLG
7	negative regulation of protein binding	GO:032091	10.1	SLPI, CAV1, MAPK8, MYC
8	response to growth factor stimulus	GO:070848	10.1	FAS, FASLG, MYC
9	regulation of cell adhesion mediated by integrin	GO:033628	9.9	PLAU, PTK2, PIK3CG
10	cellular response to lithium ion	GO:071285	9.9	PPARG, FAS, CDH1
11	negative regulation of cell-cell adhesion	GO:022408	9.6	TGFB1, PTK2, CDH1
12	branching involved in ureteric bud morphogenesis	GO:001658	9.6	MYC, BCL2, CD44, GDNF
13	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	9.6	PPARG, FAS, FASLG, CDKN2A, MYC
14	replicative senescence	GO:090399	9.6	TERT, TP53, CDKN2A
15	activation of pro-apoptotic gene products	GO:008633	9.4	MAPK8, FAS, FASLG, BCL2, MYC
16	positive regulation of epithelial cell proliferation	GO:050679	9.4	TGFB1, ERBB2, MYC, VEGFC
17	negative regulation of neuroblast proliferation	GO:007406	9.4	TP53, CTNNA1, TGFB1
18	anti-apoptosis	GO:006916	9.3	GDNF, TERT, ETS1, FAS, CEBPB, MUC1
19	positive regulation of peptidyl-serine phosphorylation	GO:033138	9.3	BCL2, CD44, CAV1, TGFB1
20	response to estrogen stimulus	GO:043627	9.2	PPARG, CTNNA1, CAV1, CCND1, FAS, BCL2
21	positive regulation of cell cycle arrest	GO:071158	9.1	CDKN2A, TP53, TGFB1
22	release of cytochrome c from mitochondria	GO:001836	9.0	MYC, BCL2, TP53, TP73
23	response to gamma radiation	GO:010332	9.0	TP53, CAV1, BCL2, MYC
24	neuron apoptotic process	GO:051402	9.0	TP63, TP53, FAS, BCL2
25	induction of apoptosis by intracellular signals	GO:008629	8.8	TP53, MAPK8, BCL2, MYC
26	MAPK cascade	GO:000165	8.7	TGFB1, CAV1, MAPK1, MYC
27	cell cycle arrest	GO:007050	8.7	TGFB1, TP73, TP53, CDKN1C, CDKN2A, MYC
28	positive regulation of cell proliferation	GO:008284	8.5	TGFB1, PTK2, ETS1, FASLG, MYC, VEGFC
29	response to DNA damage stimulus	GO:006974	8.4	MYC, BCL2, CCND1, TP53, TP73
30	induction of apoptosis	GO:006917	8.3	TGFB1, PPARG, TP63, ETS1, MAPK1, FAS
31	negative regulation of transcription from RNA polymerase II promoter	GO:000122	8.2	TGFB1, PPARG, TP53, CAV1, FASLG, CDKN1C
32	negative regulation of cell growth	GO:030308	8.1	TGFB1, PPARG, TP53, CDKN2A, BCL2
33	response to drug	GO:042493	8.1	TGFB1, PPARG, CAV1, CCND1, FAS, CDH1
34	negative regulation of apoptotic process	GO:043066	8.0	CTNNA1, PTK2, TP53, MAPK8, CD44, BCL2
35	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.7	GDNF, TGFB1, PPARG, TP73, TP63, TP53
36	positive regulation of transcription, DNA-dependent	GO:045893	7.7	TGFB1, PPARG, TP73, TP63, TP53, ETS1
37	blood coagulation	GO:007596	7.5	TGFB1, PLAU, PTK2, TP53, CAV1, MAPK1
38	apoptotic process	GO:006915	7.3	EBAG9, PTK2, TP63, TP53, MAPK1, MAPK8
39	O-glycan processing	GO:016266	INF	GALNT3, , ST6GAL1, MUC6, MUC4, MUC2
40	protein N-linked glycosylation via asparagine	GO:018279	INF	MGAT3, MGAT4A, , MGAT5, ST6GAL1

Molecular functions related to bile duct carcinoma according to GeneDecks:

(show all 8)

id	Name	GO ID	Score	Top Affiliating Genes
1	taste receptor activity	GO:008527	10.3	TAS1R3, TAS1R1, TAS1R2
2	sweet taste receptor activity	GO:033041	10.0	TAS1R3, TAS1R2
3	histone deacetylase regulator activity	GO:035033	9.4	MAPK8, TP53
4	transcription factor binding	GO:008134	8.2	TP73, TP53, ETS1, CDKN2A, CEBPB, BCL2
5	enzyme binding	GO:019899	8.2	SLPI, TGFB1, PPARG, TP53, CAV1, CCND1
6	identical protein binding	GO:042802	7.9	SYP, TP73, TP63, TP53, ERBB2, FAS
7	protein heterodimerization activity	GO:046982	7.7	TAS1R2, TAS1R1, TAS1R3, TGFB1, TP53, ERBB2
8	protein binding	GO:005515	INF	SLPI, IGF2BP3, CAV1, ETS1, , ERBB2